Medicare Director: ‘Bona-Fide’ Generic Marketing Likely Product-Specific For IRA

CMS won’t put a number on ‘bona fide” generic and biosimilar competition. Medicare's head also discussed how it will ensure rebates don’t disadvantage drugs with government-negotiated prices.